Kidney lipoma

Summary

Kidney lipoma (MONDO:0000968) is a disease. A subtype of kidney benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	kidney lipoma
Mondo ID	MONDO:0000968
DOID	DOID:10194
NCIT	C5101
UMLS	C1335744
MedGen	277588
Anatomy (UBERON)	UBERON:0002113
Is cancer (heuristic)	no

Also known as: kidney lipoma · lipoma of kidney · lipoma of the kidney · renal lipoma

Disease family

This is a subtype of kidney benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign urinary system neoplasm › kidney benign neoplasm › kidney lipoma

Related subtypes (11): benign cystic nephroma, renal adenoma, nephrogenic adenofibroma, kidney oncocytoma, nephrogenic adenoma, kidney angiomyolipoma, renal leiomyoma, benign metanephric tumor, benign neoplasm of renal pelvis, benign mesonephroma, nephroma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.